Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Yidu Tech Inc.
醫渡科技有限公司
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 2158)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2026

The board (the "**Board**") of directors (the "**Directors**") of Yidu Tech Inc. (the "**Company**", together with its subsidiaries and consolidated affiliated entities, the "**Group**") is pleased to announce the unaudited consolidated interim results of the Group for the six months ended 30 September 2026 (the "**Reporting Period**"), together with the comparative figures for the six months ended 30 September 2025. The results have been reviewed by the Company's audit committee.

In this announcement, "we", "us", and "our" refer to the Company and where the context otherwise requires, the Group.

FINANCIAL HIGHLIGHTS

	Six months ended 30 September		
	2026	2025	Change (%)
	(RMB'000, except percentages)		
Revenue	**377,040**	358,105	5.3%
— AI for Medical	**122,867**	122,850*	0.0%
— AI for Life Sciences	**201,531**	184,751*	9.1%
— AI for Care	**52,642**	50,504*	4.2%
Gross profit	**128,554**	134,027	(4.1%)
Operating profit/(loss)	**63,298**	(15,719)	a turnaround from loss to profit
Profit/(loss) for the period	**61,311**	(15,760)	a turnaround from loss to profit
Profit/(loss) attributable to owners of the Company	**56,550**	(14,602)	a turnaround from loss to profit

* To better reflect the actual business, the revenue amounts of the comparable operating segments for the same period of the last year have been adjusted accordingly.

The Board did not recommend the distribution of an interim dividend for the six months ended 30 September 2026.

BUSINESS OVERVIEW

The global medical AI industry is moving from technical validation and point solutions into a new phase characterized by scaled deployment and value realization. As artificial intelligence rises to a national-level systematic initiative, policy guidance, data factor reform, and advances in large-model capabilities are combining to accelerate the integration of medical AI into core business processes such as clinical diagnosis and treatment, medical research, drug development, and health protection. Customer demand is also shifting from the purchase of point tools to systematic solutions that can be truly embedded into business processes and continuously create clinical and operational value. As an enterprise with long-term deep expertise in medical data intelligence, Yidu Tech leverages more than a decade of real-world scenario accumulation and its self-developed technology system, continuing to take its "AI Medical Brain" YiduCore as the core to deepen its full-chain intelligent ecosystem spanning "healthcare — pharmaceuticals — insurance — patients" and consolidate its first-mover advantage as the industry moves from building technical capabilities to systematic empowerment.

During the Reporting Period, the Group remained committed to its focused strategy by further deepening its engagement with core customers and presence in key businesses, driving steady improvements in operational quality and profitability. Against the backdrop of continuously released favorable industry policies and accelerating demand for medical AI, both our order volume and revenue quality have improved. For the six months ended 30 September 2026, the Group's total revenue reached RMB377.0 million, representing a year-on-year increase of 5.3%. By continuously optimizing its cost structure and improving synergy efficiency across business segments, the Group recorded a profit of RMB61.3 million for the period. As of the end of the Reporting Period, the Group's cash and cash equivalents, term deposits, pledged bank deposits, restricted bank balance and deposits amounted to RMB2,162.3 million, and its cash reserves remained ample. These achievements validate the sustained competitiveness of the Company's technologies and products in the industry, and reinforce its foundation for capturing future market opportunities and achieving high-quality growth.

As the Group's core algorithm engine, the "AI Medical Brain" YiduCore continued to evolve during the Reporting Period. The Company continued to advance the training and iteration of large models in the vertical healthcare domain, released EYWA 6.0, a next-generation data-intelligence hub, and moved medical intelligent agents into the stage of scaled deployment. Through a "unified foundation supporting multiple applications (一底座多應用)" model, the Company fully deployed full-scenario solutions across "healthcare — pharmaceuticals — insurance — patients", further consolidating its technology foundation and competitive edge in the medical AI field.

By segment, in AI for Medical segment, we have provided solutions to 141 renowned hospitals in China and 53 regulators and policymakers as of the end of the Reporting Period. The accelerated deployment of core products, including the AI middle platform, Clinical Assistant Copilot and Yidu Smart Evidence (醫渡智循), has driven the full-scale implementation of medical intelligent agents across multiple hospitals and facilitated public hospitals moving from experience-based management to data-driven precision governance. In AI for Life Sciences segment, 16 of the world's top 20 multinational pharmaceutical companies have become our customers, with a revenue retention rate of 82.7% for the top 20 customers. During the Reporting Period, we completed 552 clinical studies and successfully supported the accelerated approval and launch of multiple first-in-class innovative drugs. In AI for Care segment, we maintained a leading position in tier-one cities. We have been the main operation platform for Beijing Hui Min Bao (北京惠民保) for six consecutive years and for Shenzhen Hui Min Bao (深圳惠民保) for four consecutive years. The cumulative scale of enrollment and claims continued to expand. Leveraging YiduCore's disease insights, risk identification and operational capabilities, we continued to provide multi-tiered and affordable health protection services to tens of millions of urban residents, promoting the implementation of inclusive protection, chronic disease management and patient services in more regions.

YiduCore

During the Reporting Period, YiduCore, the "AI Medical Brain" and core algorithm engine of the Company, continued to evolve. Leveraging the disease knowledge graph, medical semantic understanding capabilities and scenario-based model training capabilities accumulated from more than a decade of deep engagement in real-world medical scenarios, YiduCore, through a reinforced closed loop of "data-driven algorithms, algorithms empowering scenarios, and scenarios feeding back into data," continued to transform data into medical cognition and medical cognition into reusable AI capabilities, creating a flywheel effect of mutually reinforcing dynamics among "technology, applications, and data" and driving AI capabilities from single-point breakthroughs toward systematic and large-scale deployment in real-world scenarios. The Company has long been building data and modeling capabilities around the entire process of disease occurrence, development, diagnosis, treatment, and long-term management. Leveraging full-course, high-value longitudinal data governance capability, treatment, and follow-up, we continuously deepened YiduCore's ability to understand disease essence, clinical decision-making pathways, and real-world diagnostic and treatment practices.

In terms of AI model R&D, the Company continued to strengthen the training and iteration of large models in the vertical healthcare domain, achieving simultaneous improvements in core capabilities such as ultra-long context, medical knowledge understanding and complex reasoning. The Company released EYWA 6.0, a next-generation data-intelligence hub, building AI-ready data-intelligence infrastructure that supports large model training, intelligent agent development and multi-scenario applications. In addition, through upper-layer agent technologies, the Company significantly reduced the capability requirements and computing power consumption of foundation models without compromising performance, supporting complex clinical scenarios with an optimized cost structure, and achieved full-chain adaptation of domestic and international high-end chips in the vertical healthcare domain, providing a solid guarantee for the scaled implementation of its technologies.

Medical intelligent agents have entered the stage of scaled deployment. The Company has established full-chain capabilities spanning "creation — application — evaluation" and has achieved frontline application in multiple renowned hospitals. Dr. Copilot, the physician clinical assistant, serves as a unified foundation and orchestration engine and is deeply embedded in the entire pre-consultation, in-consultation and post-consultation workflow, with active physician usage and continuously accumulating usage habits. The clinical evidence-based intelligent agent Yidu Smart Evidence (醫渡智循) is characterized by being evidence-based, traceable and actionable. It provides physicians with one-stop services including evidence-based Q&A, literature retrieval and original-source traceability. Over one hundred AI medical assistants cover high-frequency clinical scenarios such as assessment, diagnosis, medication, patient education and documentation, significantly improving physician efficiency. Meanwhile, the Company has jointly built a specialty and disease-specific intelligent agent matrix with multiple top-tier tertiary hospitals, and has jointly developed the "CACA Guideline Assistant," traceable AI medical records and the evidence-based traditional Chinese medicine intelligent agent "Xiao Huangqi (小黃岐)," among others. Yidu Smart Management (醫渡智管) and Yidu Smart Research (醫渡智研) serve hospital operations and clinical research, respectively, forming a collaborative intelligent agent system covering clinical care, research and management.

In terms of scenario deployment, YiduCore is no longer merely a backend technology foundation,but is progressively embedded into the high-frequency workflows of physicians, researchers, and hospital administrators, forming a "unified foundation supporting multiple applications (一底座多應用)" model that comprehensively covers all scenarios across "healthcare-pharmaceuticals-insurance-patients" ecosystem. Through the AI middle platform, the Company builds large-model capabilities that enable users to independently develop intelligent applications. For clinical trials, the Company launched a patient recruitment intelligent agent based on a medical record understanding large model, improving the efficiency of trial recommendations and the utilization of medical record data. It also provides physician empowerment tools that support the generation of popular science content and the extraction of research insights. Leveraging these capabilities, the Company continues to help customers expand the depth and breadth of AI applications across various medical scenarios, driving the scaled and trustworthy implementation of medical AI driven by both data and intelligence.

AI for Medical

In the AI for Medical segment, we continued to deepen the integration of medical data intelligence and artificial intelligence technologies. Focusing on three major directions of building high-quality data foundations, enabling intelligent transformation of core medical businesses, and expanding the industry innovation ecosystem, we drove the scaled application of AI technologies across medical institutions and regional health systems. During the Reporting Period, revenue from this segment amounted to RMB122.9 million, with a gross margin of 52.3%. As of the end of the Reporting Period, we had a total of 141 renowned hospital customers and 53 regulatory authority and policymaker customers.

Extending from medical data governance to high-quality data foundations: During the Reporting Period, our core product, the next-generation data-intelligence hub YiduEywa, was upgraded to version 6.0. Centered on high-quality data asset production, full-domain data weaving, medical knowledge integration and model scenario empowerment, it has established AI-ready data infrastructure for hospitals in the large-model era. We also launched a medical dataset refinement platform, which, focusing on data sampling, extraction and labeling, has established a fully automated production pipeline for high-quality datasets for customers.

In terms of implementation, we won bids for projects including the new-generation big data platform of the First Affiliated Hospital of Chongqing Medical University and the hospital-wide data center of Fuling Hospital Affiliated to Chongqing University, continuing to expand the market for data foundation construction in large medical institutions. In addition, we assisted the Third Affiliated Hospital of Zhejiang Chinese Medical University in building a specialty dataset for tinnitus and deafness in traditional Chinese medicine, which obtained a data property rights registration certificate, and facilitated a data intellectual property licensing cooperation between the Eye Hospital of Wenzhou Medical University and Santen Pharmaceutical, deeply empowering data factor reform.

Extending from intelligent applications in renowned hospitals to a replicable and scalable specialty AI application system: Leveraging YiduCore, we continued to deepen our work in key disease and specialty areas such as oncology, hematology, ophthalmology, immunology and traditional Chinese medicine. Through joint innovation with high-level medical institutions and clinical experts, we accelerated the deep integration of clinical experience, specialty disease knowledge and artificial intelligence technologies. With the AI middle platform as the foundation, Clinical Assistant Copilot as the clinical application entry point, and Yidu Smart Evidence (醫渡智循) as the evidence-based decision-making and intelligent orchestration engine, we are driving the upgrading of medical AI from single-point technology applications to systematic specialty empowerment.

During the Reporting Period, we entered into a strategic cooperation with Zhongda Hospital Southeast University. Leveraging the high-quality evidence-based system of the liver disease diagnosis and treatment intelligent agent, we further expanded core scenarios such as assisted diagnosis and treatment, medical record quality control and smart services, and jointly built a specialty collaboration and promotion system with six alliance hospitals. We also jointly launched a weight management intelligent agent with Zhongshan Hospital Affiliated to Fudan University and the Chinese Alliance for Obesity Diagnosis and Treatment in Endocrinology and Metabolism. Integrating standardized clinical management, intelligent patient intervention and multicenter research translation, it has been promoted and applied among alliance member institutions; the alliance brings together more than 500 public medical institutions nationwide. Meanwhile, we continued to enrich our specialty intelligent agent product offerings by launching "Xiao Huangqi (小黃岐)", the TCM evidence-based intelligent agent of Yidu Smart Evidence (醫渡智循), and jointly releasing, with the First Affiliated Hospital of Nanchang University, an emergency teaching intelligent agent, a cardiovascular digital doctor popular science intelligent agent, and other intelligent agents. We have developed over 400 specialist-task agents that deliver quantifiable clinical value. For instance, in real-world deployment for discharge summary generation at a hospital, the adoption rate of content produced by the medical record generation agent was 80%–91.5%.

Expanding from hospital-level applications to regional-level platforms and the national-level innovation ecosystem: While continuing to deepen cooperation with hospital customers, we further leveraged our comprehensive advantages to participate in the construction of regional-level platforms and the national-level medical AI innovation application ecosystem, driving the extension of medical AI capabilities toward cross-institutional collaboration and regional resource integration.

During the Reporting Period, we won bids for projects at the First Affiliated Hospital of Xi'an Jiaotong University, including the intelligent infectious disease early warning project, the virtual simulation training center for infectious disease surveillance and epidemiological investigation, and the infectious disease big data platform, continuing to advance the application of artificial intelligence in infectious disease surveillance and early warning and public health management. We jointly established a Joint Laboratory for Intelligent Clinical Research with the Beijing Health Big Data and Policy Research Center (北京市衛生健康大數據與政策研究中心), carrying out cooperation in research on the compliant utilization of health and medical data, drug clinical trial and medical research services, and talent cultivation in health and medical data and artificial intelligence. We also entered into a strategic cooperation with the operating entity of the Zhejiang National Artificial Intelligence Application Pilot Base (Medical), further expanding our cooperation with national-level medical AI pilot bases following Beijing and Henan.

AI for Life Sciences

During the Reporting Period, the AI for Life Sciences segment recorded revenue of RMB201.5 million, representing a year-on-year increase of 9.1%. The Company is committed to providing life sciences customers with AI-enabled intelligent services covering the entire product lifecycle. 16 of the world's top 20 multinational pharmaceutical companies have become the Company's customers, with customer coverage and stickiness continuing to improve and a revenue retention rate of 82.7% for the top 20 customers. During the Reporting Period, the Company successfully supported the accelerated approval and launch of multiple first-in-class innovative drugs and, leveraging its AI-driven integrated platform, provided innovative pharmaceutical companies with end-to-end support from market and project research and registration strategy to clinical operations, including assisting an innovative pharmaceutical company in obtaining National Medical Products Administration (NMPA) approval for a new indication of mild-to-moderate atopic dermatitis for one of its innovative drugs.

In terms of clinical research, we have completed 552 clinical studies, including registrational clinical trials initiated by pharmaceutical companies and investigator-initiated trials (IITs). We have carried out 330 prospective and retrospective real-world projects. In addition, the Company continued to advance the integration of AI technologies into the entire clinical research workflow. During the Reporting Period, the Company undertook the construction of a clinical research information platform for a local health authority, responsible for building the clinical research matching service system and the participant online registration system, connecting the entire process from the matching of innovation needs to subject enrollment. Leveraging the jointly established Joint Laboratory for Intelligent Clinical Research, the Company focused on key areas such as clinical trial protocol optimization, participant recruitment, intelligent quality control and remote monitoring, exploring the enabled application of data intelligence. The intelligent clinical trial screening and recruitment system the Company built for a tertiary oncology specialty hospital went live, integrating participant screening with the hospital's Hospital Information System (HIS) diagnosis and treatment workflow and covering outpatient and inpatient scenarios to form a service loop of "intelligent screening, physician referral, project review and end-to-end tracking." Through the internet hospital recruitment platform, it also enabled the unified aggregation of ongoing projects and online patient registration, significantly improving the efficiency of matching clinical trials with patients.

During the Reporting Period, in the area of real-world studies and post-marketing evidence generation, we secured project orders from multiple internationally renowned pharmaceutical companies, covering core therapeutic areas such as oncology, cardiovascular diseases and chronic respiratory diseases. We implemented multiple treatment pattern studies, real-world cohort studies and systematic reviews and meta-analyses, and carried out regional database collaborations and population evidence studies focusing on rare diseases and chronic respiratory diseases. In addition, the Company joined an AI pharmaceutical innovation consortium initiated by a national-level innovative drug laboratory, and deepened strategic cooperation with multiple internationally renowned pharmaceutical companies in areas such as AI-enabled clinical research, real-world studies and patient management.

Our team has an average of more than 10 years of experience in fields including clinical research, data science, epidemiology, biostatistics, medical informatics and artificial intelligence. By cultivating a high-quality talent pool, we continue to improve project operational efficiency and customer experience, ensuring that we maintain a leading position in a highly competitive market.

AI for Care

In the AI for Care segment, leveraging YiduCore's disease insights, AI algorithm capabilities and years of operational experience, we continued to provide multi-tiered health protection and intelligent health management services to tens of millions of urban residents. During the Reporting Period, revenue from this segment amounted to RMB52.6 million, a year-on-year increase of 4.2%, with a gross margin of 63.2%.

In the field of inclusive health protection, we continued to deepen our presence in core cities such as Beijing and Shenzhen. Leveraging our mature platform operating system and artificial intelligence capabilities, we provided one-stop solutions covering product operations, intelligent claims and user services to cities with tens of millions of residents, further strengthening our leading position in the inclusive health sector in tier-one cities.

With respect to Beijing Hui Min Bao (北京惠民保), we have served as the main operating platform for six consecutive years, accumulating over 19 million insured and processing more than 740,000 claims. Leveraging AI technologies and compliant data application capabilities, the Company has innovatively developed an intelligent fast-claims service model, significantly optimizing the claims settlement experience. Approximately 90% of approved claims under the Beijing Hui Min Bao (北京惠民保) program are processed through the fast-claims channel. With user and relevant institutional authorization, the platform enables intelligent and efficient processing of an average of more than 10,000 claims per month, improving claims processing efficiency by 60%–70% compared with traditional models.

While continuously improving medical protection services, Beijing Hui Min Bao (北京惠民保) further expanded proactive health management services. Centered on the early detection of major diseases and daily health management needs, we innovatively launched three services — early cancer screening, Alzheimer's disease (AD) early screening and an AI health steward — further enriching the service offerings of inclusive health protection.

With respect to Shenzhen Hui Min Bao (深圳惠民保), we have served as the main operating platform for four consecutive years and the number of insured individuals has surpassed 6 million for four consecutive years, covering around 35% of basic medical insurance participants in Shenzhen, ranking among the top nationwide, with cumulative claims exceeding 745,000 cases.

In the field of chronic disease management, we continued to extend disease-centered digital health management solutions to the primary healthcare system. Building on the phased application results of the diabetes digital therapeutics project in Hainan Province, we further promoted the relevant technological capabilities and service models to Tianjin, Taiyuan City in Shanxi Province, Chaoyang District in Beijing, and other regions, while continuously expanding the range of chronic diseases covered and enriching service scenarios. We have gradually formed a digital service model covering the entire process of primary-level chronic disease management, promoting the standardized and intelligent development of chronic disease management services.

In the future, the Company will continue to build expertise-based barriers in both technology and operations, and provide long-term support for the development of the multi-tiered medical protection system and universal health management.

Business Outlook

Looking ahead, as artificial intelligence technologies accelerate their integration with real-world medical business scenarios, medical AI is further advancing toward specialized, systematic and scaled applications. Collaborative innovation across high-quality medical data, disease knowledge systems and intelligent agent technologies will continue to drive AI to unlock value in core areas such as clinical diagnosis and treatment, medical research, drug development and health management. We believe that the long-term competitiveness of medical AI depends not only on model technologies themselves, but more on a deep understanding of diseases and clinical scenarios, as well as the ability to translate technological capabilities into sustainable and scalable products and services.

As an enterprise with long-term deep expertise in medical data intelligence and artificial intelligence, Yidu Tech will continue to adhere to its focused strategy, with YiduCore at the core, and deepen its business layout that spans the entire "medical treatment, drugs, insurance and patients" value chain. While continuing to consolidate operational quality and profitability, we will place greater emphasis on the synergy between technological innovation and business growth. Centered on high-quality data infrastructure, disease intelligence productization and scaled application capabilities, we will further strengthen our core competitive barriers and drive the Company to deepen its transition from the accumulation of technology and project capabilities toward productization, platformization and sustained commercial value creation. In the future, we will focus on advancing the following directions:

(i) Deepen YiduCore's disease intelligence capabilities and build a next-generation technology and data infrastructure for medical AI applications. Leveraging our accumulated experience in real-world medical data processing, disease knowledge graphs and medical artificial intelligence capabilities, we will continue to improve our technology system spanning high-quality data generation, medical knowledge organization, disease modeling and intelligent decision-making. As medical AI applications continue to deepen, we will further strengthen the development of high-quality medical datasets, medical knowledge reasoning, multimodal data fusion and intelligent agent collaboration, and promote the transformation of medical data resources into high-value data assets usable for AI training, validation and application. At the same time, we will continue to improve the standardization and reusability of our underlying technological capabilities, providing unified, reliable and scalable intelligent technology support for medical institutions, life sciences companies and health management services.

(ii) Deepen our disease-centered product system and drive the scaling and replication of specialty AI capabilities from joint innovation. We will continue to deepen our cooperation in key diseases and specialty areas such as oncology, hematology, cardiovascular and cerebrovascular diseases, metabolic diseases and traditional Chinese medicine with high-level medical institutions and clinical experts, to transform real-world data insights, disease knowledge and clinical practice experience into reusable specialty disease models, intelligent agent products and full-disease-course solutions. While continuing to advance innovative applications in top-tier hospitals, we will place greater emphasis on leveraging specialty alliances, multicenter cooperation and regional medical networks to promote the adoption of mature specialty AI capabilities by more medical institutions, gradually forming a development mechanism in which disease knowledge accumulation, product application and real-world scenario feedback mutually reinforce each other, and enhancing our scaled delivery capabilities and commercial value.

(iii) Strengthen platformization and ecosystem collaboration capabilities, and continuously improve the scaled application and commercialization efficiency of medical AI. We will further promote collaboration among the AI middle platform, Clinical Assistant Copilot, Yidu Smart Evidence (醫渡智循) and various specialized intelligent agents, facilitating the deep embedding of artificial intelligence capabilities into clinical, research, management and health service workflows. Building on continued deep application at the hospital level, we will actively participate in the construction of regional-level medical platforms, clinical research infrastructure and the national-level artificial intelligence innovation application ecosystem, driving the expansion of our technologies and products from single-institution applications to cross-institutional collaboration and regional deployment. At the same time, we will pay greater attention to product standardization, delivery efficiency and long-term customer value, explore more flexible and sustainable product service and commercialization models, and continue to improve operational efficiency and profitability while expanding business coverage.

As for AI for Medical, we will continue to deepen the "one horizontal and one vertical" development strategy and drive our business toward high-quality AI data infrastructure, specialty intelligent applications and industry-level platform development. Horizontally, leveraging product systems such as the data middle platform, AI middle platform, Clinical Assistant Copilot and Yidu Smart Evidence (醫渡智循), we will continue to expand the application of medical AI in scenarios including hospitals, regional healthcare and public health, and actively participate in the construction of regional-level research service platforms and the medical AI innovation ecosystem. Vertically, we will focus on key diseases and specialty areas, continue to advance the development of high-quality specialty disease datasets, disease models and intelligent agent products, deepen collaboration with high-level medical institutions and specialty alliances, and promote the replication and application of mature products across multiple institutions and scenarios. Through the coordinated development of technology foundations, specialty products and medical networks, we will further enhance the Company's comprehensive competitiveness in medical AI infrastructure and intelligent applications.

As for AI for Life Sciences, we will continue to leverage YiduCore's strengths in disease understanding, real-world data insights and medical intelligence to drive deeper AI empowerment across the full lifecycle of drugs and medical devices. Focusing on key areas such as clinical development, patient recruitment, data collection, intelligent quality control, real-world studies and post-marketing evidence generation, we will continue to advance the integration of AI technologies with our i-series solutions, and improve the automation and intelligence of clinical research and project delivery efficiency. At the same time, we will deepen the application of real-world evidence in areas such as drug value assessment, medical strategy and commercialization decisions, drive life sciences services to extend from research execution and evidence generation toward higher-value R&D and decision support, and continue to expand long-term cooperation with leading global pharmaceutical companies and innovative biopharmaceutical companies.

As for AI for Care, we will continue to rely on YiduCore's disease insights, health risk identification capabilities and years of accumulated scaled operational experience to further deepen the integration of artificial intelligence with multi-tiered medical protection and health management services. While consolidating our advantages in the inclusive health protection business in core cities, we will further enhance intelligent claim settlement, refined operations and health service capabilities, and promote closer linkages between medical protection and disease prevention, health intervention and long-term management. At the same time, focusing on key diseases and population health needs, we will continue to expand application scenarios such as early disease screening, chronic disease management and digital therapeutics, and promote the replication of mature disease management models to more regions and populations. In the future, we will further leverage the synergistic advantages of medical data intelligence, disease management and health protection to explore a full-cycle service model spanning risk identification, proactive intervention, medical protection and long-term health management, and continue to expand the value and commercialization potential of our AI-driven health management business.

Looking ahead, adhering to its mission of "making precision healthcare accessible to everyone," Yidu Tech will continue to be guided by real clinical needs and the value of disease management and promote the coordinated development of YiduCore's technological capabilities and its three major business segments. While deepening its technological barriers and medical expertise, the Company will further enhance product reusability, scaled application efficiency and long-term commercial value, and create sustainable returns for shareholders, customers and healthcare ecosystem partners.

Revenue

Our revenue increased from RMB358.1 million for the six months ended 30 September 2025 to RMB377.0 million for the six months ended 30 September 2026. The increase was primarily attributable to the increase in revenue from AI for Life Sciences segment and AI for Care segment.

AI for Medical. Revenue from AI for Medical remained stable, at RMB122.9 million for both the six months ended 30 September 2025 and 2026.

AI for Life Sciences. Revenue from AI for Life Sciences increased from RMB184.7 million for the six months ended 30 September 2025 to RMB201.5 million for the six months ended 30 September 2026, which was mainly due to the increase in pharmaceutical sales revenue.

AI for Care. Revenue from AI for Care increased from RMB50.5 million for the six months ended 30 September 2025 to RMB52.6 million for the six months ended 30 September 2026, primarily due to the increase in revenue from the Hui Min Bao (惠民保) business.

Cost of sales and services

Our cost of sales and services increased from RMB224.1 million for the six months ended 30 September 2025 to RMB248.5 million for the six months ended 30 September 2026.

AI for Medical. Cost of sales and services from the AI for Medical segment increased from RMB58.5 million for the six months ended 30 September 2025 to RMB58.7 million for the six months ended 30 September 2026.

AI for Life Sciences. Cost of sales and services from AI for Life Sciences increased overall, from RMB145.9 million for the six months ended 30 September 2025 to RMB170.4 million for the six months ended 30 September 2026, primarily due to the increase in the cost of pharmaceutical sales.

AI for Care. Cost of sales and services from the AI for Care segment decreased from RMB19.7 million for the six months ended 30 September 2025 to RMB19.4 million for the six months ended 30 September 2026, primarily due to the decrease in employee-related costs and benefits.

Gross profit and gross margin

As a result of the foregoing, our overall gross profits for the six months ended 30 September 2025 and 2026 were RMB134.0 million and RMB128.6 million respectively, and our overall gross margins were 37.4% and 34.1% respectively.

AI for Medical. Our gross margin in AI for Medical remained stable from 52.4% for the six months ended 30 September 2025 to 52.3% for the six months ended 30 September 2026.

AI for Life Sciences. Our gross margin in AI for Life Sciences decreased from 21.0% for the six months ended 30 September 2025 to 15.4% for the six months ended 30 September 2026, primarily due to the increased proportion of pharmaceutical sales.

AI for Care. Our gross margin in AI for Care increased from 61.0% for the six months ended 30 September 2025 to 63.2% for the six months ended 30 September 2026, primarily due to improved operational efficiency.

Selling and marketing expenses

Our selling and marketing expenses remained relatively stable, decreasing from RMB73.5 million for the six months ended 30 September 2025 to RMB71.0 million for the six months ended 30 September 2026.

Selling and marketing expenses as a percentage of revenue decreased from 20.5% for the six months ended 30 September 2025 to 18.8% for the six months ended 30 September 2026, reflecting improved efficiency in sales and marketing.

Administrative expenses

Our administrative expenses decreased from RMB60.4 million for the six months ended 30 September 2025 to RMB47.1 million for the six months ended 30 September 2026, primarily attributable to the decrease in employee benefits and expenses for employees engaged in administrative functions from RMB38.9 million to RMB27.8 million, as well as the decrease in other professional service fees.

Administrative expenses as a percentage of revenue decreased from 16.9% for the six months ended 30 September 2025 to 12.5% for the six months ended 30 September 2026.

Research and development expenses

Our research and development expenses decreased from RMB84.8 million for the six months ended 30 September 2025 to RMB77.6 million for the six months ended 30 September 2026, primarily due to the decrease in employee benefits and expenses for employees engaged in research and development projects from RMB55.1 million to RMB46.2 million.

Research and development expenses as a percentage of revenue decreased from 23.7% for the six months ended 30 September 2025 to 20.5% for the six months ended 30 September 2026.

Operating profit/(loss)

As a result of the foregoing, the Group's operating results turned from an operating loss of RMB15.7 million for the six months ended 30 September 2025 to an operating profit of RMB63.3 million for the six months ended 30 September 2026.

Taxation

Income tax expense of the Group increased from RMB2 thousand for the six months ended 30 September 2025 to RMB3,185 thousand for the six months ended 30 September 2026.

Profit/(loss) for the period

As a result of the foregoing, our loss of RMB15.8 million for the six months ended 30 September 2025 turned into a profit of RMB61.3 million for the six months ended 30 September 2026.

Liquidity and capital resources

For the six months ended 30 September 2026, we funded our cash requirements principally from capital contributions from shareholders, financing through issuance and sale of convertible redeemable preferred shares in private placement transactions, and proceeds from initial public offering. We had cash and cash equivalents, term deposits, pledged bank deposits, restricted bank balance and deposits of RMB2,079.8 million and RMB2,162.3 million as at 31 March 2026 and 30 September 2026 respectively.

Significant investments

On 28 October 2022, Marvelous Panda Inc., a wholly-owned subsidiary of the Company, entered into a subscription agreement for the fund YD Capital I L.P. (the "Fund") with the general partner and became a limited partner of the Fund by making a cash contribution of US$40.0 million to the Fund, representing 40% of the fund commitment. As at 30 September 2026, an amount of US$13.2 million was paid by the Group. The purpose of the Fund is primarily to (i) make venture capital investments in the healthcare sector; (ii) manage, supervise and dispose of such investments; and (iii) engage in such other activities incidental or ancillary thereto as the general partner deems necessary, appropriate or advisable.

Material acquisitions and disposals

The Group did not have any material acquisitions or disposals of subsidiaries, consolidated affiliated entities or associated companies for the six months ended 30 September 2026.

Pledge of assets

As at 30 September 2026, the Group had no material pledge of assets.

Future plans for material investments or capital assets

As at 30 September 2026, the Group did not have detailed future plans for material investments or capital assets.

Foreign exchange exposure

During the Reporting Period, the Group mainly operated in China with most of the transactions settled in Renminbi. The functional currency of the Company, the subsidiaries and the consolidated affiliated entities that operate in the PRC, and the subsidiary operating in Brunei is U.S. dollar, Renminbi and U.S. dollar, respectively. During the six months ended 30 September 2026, we had currency translation losses of RMB82.9 million and net foreign exchange losses of RMB2.7 million, as compared with currency translation losses of RMB33.4 million and net foreign exchange losses of RMB1.9 million during the six months ended 30 September 2025. We did not hedge against any fluctuation in foreign currency during the six months ended 30 September 2025 and 2026.

Contingent liabilities

As at 30 September 2026, we did not have any material contingent liabilities (as at 31 March 2026: nil).

Capital commitment

As at 30 September 2026, capital commitment of the Group was nil (as at 31 March 2026: nil).

Investment commitment

As at 30 September 2026, investment commitment of the Group was RMB182.9 million (as at 31 March 2026: RMB201.9 million), mainly for the outstanding contribution from Marvelous Panda Inc., a wholly-owned subsidiary of the Company, to the Fund YD Capital I L.P.

Employees and remuneration

As at 30 September 2026, the Group had a total of 745 employees, with 342 employees based in Beijing, 69 employees based in Shanghai and 334 employees based in offices in other cities in China and overseas. The following table sets forth the total number of employees by function as at 30 September 2026:

Function	**Number of employees**
Product Development and Technology	386
Medical Function	174
Sales and Marketing	118
General and Administrative	67
Total	745

The total remuneration cost incurred by the Group for the six months ended 30 September 2026 was RMB161.3 million, as compared to RMB188.7 million for the six months ended 30 September 2025. The Company has also adopted and amended a post-IPO share award scheme and adopted a post-IPO share option scheme which was terminated on 25 August 2023 but the provisions of the post-IPO share option scheme shall remain in full force to the extent necessary to give effect to the exercise of any options granted prior to the termination.

Subsequent events

As of the date of this announcement, no significant events occurred after the Reporting Period which require additional disclosures or adjustments.

CORPORATE GOVERNANCE AND OTHER INFORMATION

The Company was incorporated in the Cayman Islands on 9 December 2014 as an exempted company with limited liability, and the shares of the Company were listed on the Main Board of the Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") on 15 January 2021.

The Board is committed to achieving high corporate governance standards. The Board believes that high corporate governance standards are essential in providing a framework for the Group to safeguard the interests of shareholders and to enhance corporate value and accountability.

Compliance with Corporate Governance Code

During the Reporting Period, the Company has complied with the applicable provisions of the Corporate Governance Code (the "**Corporate Governance Code**") set out in Appendix C1 to the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

Compliance with the Model Code for Securities Transactions by Directors

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the "**Model Code**") as set out in Appendix C3 of the Listing Rules as its own code of conduct regarding directors' securities transactions.

Specific enquiry has been made of all the Directors and the relevant employees and they have confirmed that they have complied with the Model Code during the Reporting Period.

Audit Committee

The Group has established an audit committee comprising three members, being Dr. Fan Wenhui, Ms. Pan Rongrong and Prof. Zhang Linqi, with Ms. Pan Rongrong (being the Company's independent non-executive Director with the appropriate professional qualifications) as chair of the audit committee.

The audit committee has reviewed the interim condensed consolidated financial information of the Group for the six months ended 30 September 2026 and has met with the independent auditor, PricewaterhouseCoopers. The audit committee has also discussed matters with respect to the accounting policies and practices adopted by the Company and internal control and financial reporting matters with senior management members of the Company.

Auditor's scope of work

The Company's external auditor, PricewaterhouseCoopers, has performed a review of the Group's unaudited interim condensed consolidated financial information for the six months ended 30 September 2026 in accordance with the International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". PricewaterhouseCoopers confirmed that nothing has come to their attention that causes them to believe that the interim financial information is not prepared, in all material respects, in accordance with International Accounting Standard 34 "Interim Financial Reporting".

OTHER INFORMATION

Purchase, sale or redemption of the Company's listed securities

During the Reporting Period, neither the Company nor any of its subsidiaries or consolidated attributed entities has purchased, sold or redeemed any of the Company's listed securities.

Material litigation

The Company was not involved in any material litigation or arbitration during the Reporting Period. The Directors are also not aware of any material litigation or claims that are pending or threatened against the Group during the Reporting Period and up to the date of this announcement.

Use of proceeds from global offering

On 15 January 2021, the shares of the Company were listed on the Main Board of the Stock Exchange. The net proceeds from the global offering (following full exercise of the Over-allotment Option, as defined in the prospectus of the Company dated 31 December 2020 (the "**Prospectus**")) were approximately RMB3,825 million (the "**Net Proceeds**"), which are intended to be applied in the manner set out in the Prospectus. There was no change in the intended use of proceeds as previously disclosed.

Set out below is the status of use of proceeds from the global offering as at 30 September 2026.

Purpose	% of use of proceeds	Net proceeds *(RMB million)*	Unutilised amount as at 31 March 2026 *(RMB million)*	Amount used for the six months ended 30 September 2026 *(RMB million)*	Unutilised amount as at 30 September 2026 *(RMB million)*	Actual/expected time of full utilisation
Strengthen our core capabilities	35%	1,339	–	–	–	31 March 2026
Further our business expansion	35%	1,339	–	–	–	30 September 2024
Further enrich our ecosystem through strategic partnerships, investments and acquisitions	20%	765	626	24.2	601.8	31 March 2030
Working capital and general corporate purposes	10%	382	–	–	–	31 March 2025

The above Net Proceeds were translated with spot rates on the Listing Date, while the cash and cash equivalents, term deposits, restricted bank balance and deposits as of 30 September 2026 were translated with spot rates on its balance sheet date.

As at 30 September 2026, the Company had utilised RMB3,223.2 million of the Net Proceeds.

Interim dividend

The Board does not recommend the distribution of an interim dividend for the six months ended 30 September 2026.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

	Note	Six months ended 30 September	
		2026	2025
		RMB'000	*RMB'000*
		(Unaudited)	(Unaudited)
Revenue from contracts with customers	*5*	**377,040**	358,105
Cost of sales and services	*5, 6*	**(248,486)**	(224,078)
Gross profit		**128,554**	134,027
Selling and marketing expenses	*6*	**(71,046)**	(73,493)
Administrative expenses	*6*	**(47,096)**	(60,375)
Research and development expenses	*6*	**(77,613)**	(84,785)
Net impairment losses on financial assets and contract assets		**(12,001)**	(36,565)
Impairment of non-financial assets		**–**	17
Other income		**60,777**	80,916
Other gains — net		**81,723**	24,539
Operating profit/(loss)		**63,298**	(15,719)
Finance income		**3,741**	2,022
Finance costs		**(577)**	(940)
Finance income — net		**3,164**	1,082
Share of losses from investments in associates		**(1,966)**	(1,121)
Profit/(loss) before income tax		**64,496**	(15,758)
Income tax expense	*7*	**(3,185)**	(2)
Profit/(loss) for the period		**61,311**	(15,760)
Profit/(loss) is attributable to:			
Owners of the Company		**56,550**	(14,602)
Non-controlling interests		**4,761**	(1,158)
		61,311	(15,760)

	Note	Six months ended 30 September	
		2026	2025
		RMB'000	*RMB'000*
		(Unaudited)	(Unaudited)
Other comprehensive loss			
Item that will not be reclassified to profit or loss:			
Currency translation differences		**(106,389)**	(71,940)
Item that will be reclassified to profit or loss :			
Currency translation differences		**23,511**	38,529
Other comprehensive loss for the period, net of tax		**(82,878)**	(33,411)
Total comprehensive loss for the period		**(21,567)**	(49,171)
Total comprehensive loss for the period is attributable to:			
Owners of the Company		**(23,449)**	(46,993)
Non-controlling interests		**1,882**	(2,178)
		(21,567)	(49,171)
Earnings/(loss) per share attributable to owners of the Company for the period (in RMB per share)			
— Basic	*8(a)*	**0.06**	(0.01)
— Diluted	*8(b)*	**0.05**	(0.01)

INTERIM CONDENSED CONSOLIDATED BALANCE SHEET

	Note	**As at 30 September 2026** ***RMB'000*** **(Unaudited)**	As at 31 March 2026 *RMB'000* (Audited)
Assets			
Non-current assets			
Property, plant and equipment		**131,979**	138,341
Right-of-use assets		**9,473**	4,000
Investment properties		**–**	1,605
Intangible assets		**52,011**	43,611
Investments accounted for using the equity method		**80,690**	82,557
Investments measured at amortized cost		**1,010,265**	1,203,976
Financial assets at fair value through profit or loss		**187,846**	83,695
Pledged bank deposits		**5,369**	5,960
Restricted bank balance and deposits		**6,392**	6,381
Total non-current assets		**1,484,025**	1,570,126
Current assets			
Inventories		**16,166**	5,068
Trade receivables	*9*	**460,772**	377,683
Contract assets		**77,013**	65,085
Other financial assets at amortized cost		**20,909**	86,368
Investments measured at amortized cost		**15,239**	53,523
Financial assets at fair value through profit or loss		**–**	19,644
Pledged bank deposits		**13,468**	1,109
Restricted bank balance and deposits		**8,964**	8,961
Term deposits		**1,613,476**	1,392,610
Cash and cash equivalents		**514,599**	664,764
Other current assets		**52,209**	70,483
Total current assets		**2,792,815**	2,745,298
Total assets		**4,276,840**	4,315,424

	Note	As at 30 September 2026 RMB'000 (Unaudited)	As at 31 March 2026 RMB'000 (Audited)
Equity			
Equity attributable to owners of the Company			
Share capital		**137**	137
Treasury shares		**(273,714)**	(273,714)
Other reserves		**12,953,668**	13,024,649
Accumulated deficits		**(9,084,483)**	(9,106,039)
		3,595,608	3,645,033
Non-controlling interests		**60,235**	58,353
Total equity		**3,655,843**	3,703,386
Liabilities			
Non-current liabilities			
Borrowings		**–**	27,000
Lease liabilities		**4,726**	4,719
Deferred income tax liabilities		**–**	3
Deferred income		**11,729**	9,042
Total non-current liabilities		**16,455**	40,764
Current liabilities			
Borrowings		**85,172**	37,970
Trade and other payables	*10*	**316,905**	356,472
Salary and welfare payable		**80,160**	99,234
Contract liabilities		**115,129**	70,931
Current income tax liabilities		**3,110**	5,264
Lease liabilities		**2,179**	1,403
Dividend payable		**1,887**	–
Total current liabilities		**604,542**	571,274
Total liabilities		**620,997**	612,038
Total equity and total liabilities		**4,276,840**	4,315,424

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL DATA

1 General information

Yidu Tech Inc. (the "**Company**") was incorporated in the Cayman Islands on 9 December 2014 as an exempted company with limited liability under the Companies Act of the Cayman Islands (Cap. 22, Law 3 of 1961 as consolidated and revised). The address of the Company is Suite#4-210, Governors Square, 23 Lime Tree Bay Avenue, PO Box 32311, Grand Cayman KY1-1209, Cayman Islands.

The Company is an investment holding company and its subsidiaries (together, the "**Group**") are primarily engaged in the provision of the following services: i) AI for Medical, ii) AI for Life Sciences, and iii) AI for Care in the People's Republic of China ("**PRC**"), Brunei and Singapore.

The interim condensed consolidated financial information comprises the interim condensed consolidated balance sheet as at 30 September 2026, the interim condensed consolidated statement of comprehensive income, the interim condensed consolidated statement of changes in equity and the interim condensed consolidated statement of cash flows for the six-month period then ended, and selected explanatory notes (the "**Interim Financial Information**").

The Interim Financial Information is presented in Renminbi ("**RMB**"), unless otherwise stated. The Interim Financial Information has been approved by the Board of Directors of the Company on 22 November 2026.

This Interim Financial Information has not been audited.

2 Basis of preparation

The Interim Financial Information for the six months ended 30 September 2026 has been prepared in accordance with International Accounting Standard 34 "Interim Financial Reporting" ("**IAS 34**").

The Interim Financial Information does not include all the notes normally included in the annual consolidated financial statements. Accordingly, it should be read in conjunction with the Group's consolidated financial statements for the year ended 31 March 2026, which have been prepared in accordance with IFRS Accounting Standards.

3 Material accounting policies

The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, except for the adoption of the new or amended standards as set out below.

3 Material accounting policies (continued)

(a) New or amended standards adopted by the Group

The Group has applied the following new or amended standards for the first time for the Group's financial year beginning on 1 April 2026:

- Amendments to IFRS 9 and IFRS 7 — Amendments to the Classification and Measurement of Financial Instruments
- Amendments to IFRS 9 and IFRS 7 — Contracts Referencing Nature-dependent Electricity
- Annual Improvements to IFRS Accounting Standards — Volume 11

The amendments listed above did not have any material impact on the amounts recognised in prior periods and are not expected to significantly affect the current or future periods.

(b) New or amended standards not yet adopted

The following new or amended standards have been published that are not mandatory for reporting periods commencing on 1 April 2026 and have not been early adopted by the Group.

	Effective date
• Amendments to IAS 21 — Translation to a Hyperinflationary Presentation Currency	1 January 2027
• IFRS 18, 'Presentation and Disclosure in Financial Statements'	1 January 2027
• IFRS 19, 'Subsidiaries without Public Accountability: Disclosures'	1 January 2027
• Amendments to IFRS 19 — 'Subsidiaries without Public Accountability: Disclosures'	1 January 2027
• IFRS 20, 'Regulatory Assets and Regulatory Liabilities'	1 January 2029

These new standards, amendments and annual improvements listed above are not expected to have a material impact on the Group in the current or future reporting periods and on foreseeable future transactions, except for the IFRS 18 presentation and disclosure in financial statements ("**IFRS 18**"). The impact of IFRS 18 should be read in conjunction with the annual consolidated financial statements for the year ended 31 March 2026.

4 Critical accounting estimates and judgements

The preparation of the Interim Financial Information requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

In preparing the Interim Financial Information, the significant judgments made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those applied in the preparation of the Group's consolidated financial statements for the year ended 31 March 2026.

5 Segment information

Disaggregation of revenue from contracts with customers

The Group's business activities, for which discrete financial information are available, are regularly reviewed and evaluated by the Chief Operating Decision Maker. As a result of this evaluation, the Group determined that it has operating segments as follows:

- AI for Medical
- AI for Life Sciences
- AI for Care

5 Segment information (continued)

	Six months ended 30 September 2026 (Unaudited)			
	AI for Medical	**AI for Life Sciences**	**AI for Care**	**Total**
	RMB'000	***RMB'000***	***RMB'000***	***RMB'000***
Revenue from contracts with customers	**122,867**	**201,531**	**52,642**	**377,040**
Cost of sales and services	**(58,667)**	**(170,430)**	**(19,389)**	**(248,486)**
Gross profit	**64,200**	**31,101**	**33,253**	**128,554**

	Six months ended 30 September 2025 (Unaudited)			
	AI for Medical	AI for Life Sciences	AI for Care	Total
	RMB'000	*RMB'000*	*RMB'000*	*RMB'000*
Revenue from contracts with customers	122,850	184,751	50,504	358,105
Cost of sales and services	(58,466)	(145,900)	(19,712)	(224,078)
Gross profit	64,384	38,851	30,792	134,027

During the six months ended 30 September 2026, due to the continued expansion of sales of pharmaceutical products driven by demand from customers, the Group unified the management of such business by transferring the operations previously reported under the AI for Medical segment and AI for Care segment into the AI for Life Sciences segment. The Group has adjusted the corresponding comparative figures for the prior period.

For the six months ended 30 September 2026, the revenue from contracts with customers of sales of pharmaceutical products in the AI for Life Sciences segment was RMB105.3 million. For the six months ended 30 September 2025, the revenue from contracts with customers of sales of pharmaceutical products in the AI for Medical segment and AI for Care segment were RMB30.3 million and RMB16.2 million, respectively, which have been reclassified into AI for Life Sciences segment accordingly.

The Company is domiciled in the Cayman Islands while the Group mainly operates its businesses in the Chinese Mainland. For the six months ended 30 September 2026 and 2025, the Group earned approximately 88% and 12%, 87% and 13% of total revenue from external customers located in the Chinese Mainland and outside the Chinese Mainland, respectively.

5 Segment information (continued)

As at 30 September 2026 and 31 March 2026, the majority of the non-current assets of the Group were located in the Chinese Mainland and Brunei.

6 Expenses by nature

Expenses included in cost of sales and services, selling and marketing expenses, administrative expenses and research and development expenses are further analysed as follows:

	Six months ended 30 September	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Employee benefits expenses	**161,256**	188,731
Cost of pharmaceutical products	**102,678**	45,306
Outsourcing services fee	**90,243**	121,902
Professional service fee	**29,083**	27,327
Travelling, entertainment and general office expenses	**23,776**	22,657
Depreciation of property, plant and equipment	**9,411**	14,183
Promotion and advertising expenses	**8,492**	7,852
Cost of hardware and software	**5,779**	3,802
Amortization of intangible assets	**5,191**	3,732
Labour dispatching	**3,479**	2,402
Auditor's remuneration	**1,899**	1,683
Taxes and surcharges	**1,181**	989
Depreciation of right-of-use assets	**751**	1,012
Other expenses	**1,022**	1,153
	444,241	442,731

7 Income tax expense

	Six months ended 30 September	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Current income tax expense	**3,188**	1
Deferred income tax (credit)/expense	**(3)**	1
	3,185	2

8 Earnings/(loss) per share

(a) Basic earnings/(loss) per share is calculated by dividing the profit/(loss) attributable to the Company's owners by the weighted average number of ordinary shares in issue during the six months ended 30 September 2026 and 2025.

The calculation of loss per share is based on the following:

	Six months ended 30 September	
	2026	2025
	(Unaudited)	(Unaudited)
Earnings/(loss) for the period attributable to owners of the Company *(RMB'000)*	**56,550**	(14,602)
Weighted average number of ordinary shares outstanding *('000)*	**1,020,610**	1,060,170
Basic earnings/(loss) per share *(in RMB per share)*	**0.06**	(0.01)

(b) Diluted earnings/(loss) per share is calculated by adjusting the weighted average number of ordinary shares outstanding to assume conversion of all dilutive potential ordinary shares.

The calculation of diluted earnings/(loss) per share is based on the following:

	Six months ended 30 September	
	2026	2025
	(Unaudited)	(Unaudited)
Earnings/(loss) for the period attributable to owners of the Company *(RMB'000)*	**56,550**	(14,602)
Weighted average number of ordinary shares outstanding *('000)*	**1,020,610**	1,060,170
Adjustments for calculation of diluted earnings per share:		
Restricted Stock Units *('000)*	**13,124**	–
Stock Options *('000)*	**15**	–
Weighted average number of ordinary shares and potential ordinary shares used as the denominator in calculating diluted earnings per share *('000)*	**1,033,749**	1,060,170
Diluted earnings/(loss) per share *(in RMB per share)*	**0.05**	(0.01)

For the six months ended 30 September 2025, there was no adjustments to calculation of diluted loss per share as the adjustment effect was anti-dilutive.

9 Trade receivables

	As at 30 September 2026 *RMB'000* (Unaudited)	As at 31 March 2026 *RMB'000* (Audited)
Trade receivables from contracts with customers		
— Third parties	**641,625**	557,486
Less: allowance for impairment of trade receivables	**(180,853)**	(179,803)
	460,772	377,683

(a) The credit terms given to trade customers are determined on an individual basis with normal credit period mainly around 180 days. The aging analysis of the trade receivables based on invoice date is as follows:

	As at 30 September 2026 *RMB'000* (Unaudited)	As at 31 March 2026 *RMB'000* (Audited)
— Up to 3 months	**234,691**	182,753
— 3 to 6 months	**46,443**	37,143
— 6 months to 1 year	**91,286**	43,933
— 1 to 2 years	**77,932**	92,363
— 2 to 3 years	**57,516**	104,764
— Over 3 years	**133,757**	96,530
	641,625	557,486
Less: allowance for impairment of trade receivables	**(180,853)**	(179,803)
	460,772	377,683

(b) Fair values of trade receivables

Due to the short-term nature of the current receivables, their carrying amounts are considered to be approximately the same as their fair values.

10 Trade and other payables

	As at 30 September 2026 *RMB'000* (Unaudited)	As at 31 March 2026 *RMB'000* (Audited)
Trade payables (a)	**128,695**	117,557
Tax payables	**11,547**	19,228
Notes payable	**5,957**	22,122
Other payables:		
— Refundable government grants	**57,000**	57,000
— Insurance claims collection payables (b)	**50,272**	51,621
— Payables for professional service fee	**17,700**	21,691
— Payables for repurchase of options	**10,533**	10,821
— Accrual for marketing and sales promotion expenses	**5,382**	2,842
— Reimbursement payable to employees	**4,697**	4,762
— Insurance premium collection payables (c)	**288**	24,872
— Others	**24,834**	23,956
	316,905	356,472

The carrying amounts of trade and other payables are considered to be approximated to their fair values, due to their short-term nature.

(a) The aging analysis of the trade payables based on invoice or accrual date at the end of each reporting period is as follows:

	As at 30 September 2026 *RMB'000* (Unaudited)	As at 31 March 2026 *RMB'000* (Audited)
— Up to 3 months	**37,180**	35,055
— 3 to 6 months	**6,978**	1,697
— 6 months to 1 year	**19,171**	11,832
— 1 to 2 years	**21,242**	26,128
— 2 to 3 years	**10,473**	11,077
— Over 3 years	**33,651**	31,768
	128,695	117,557

10 Trade and other payables (continued)

(b) Insurance claims collection payables are insurance premiums that have been collected from insurance companies but have not yet been paid to third parties as at 30 September 2026.

(c) Insurance premium collection payables are insurance premiums collected on behalf of insurance companies but not yet remitted to them as at 30 September 2026.

11 Dividends

	Six months ended 30 September	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Dividends declared by the Company to its then shareholders	**34,994**	—

For the year ended 31 March 2026, the final dividend was HK$0.04 per issued share, amounting to a total of HK$40.8 million, and was approved at the Company's annual general meeting held on 28 August 2026. No dividend has been paid or declared by the Company or the companies now comprising the Group during the six months ended 30 September 2025.

PUBLICATION OF THE INTERIM RESULTS ANNOUNCEMENT AND INTERIM REPORT

This interim results announcement is published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.yidutech.com). The interim report of the Group for the six months ended 30 September 2026 will be dispatched to the Company's shareholders and made available for review on the same websites in due course.

By order of the Board
Yidu Tech Inc.
Gong Yingying
Executive Director and Chairlady

Hong Kong, 22 November 2026

As at the date of this announcement, the executive Directors are Ms. Gong Yingying, Mr. Xu Jiming and Ms. Feng Xiaoying; and the independent non-executive Directors are Dr. Fan Wenhui, Ms. Pan Rongrong and Prof. Zhang Linqi.